Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 19

1.

Non-invasive imaging of the type 2 cannabinoid receptor, focus on positron emission tomography.

Evens N, Bormans GM.

Curr Top Med Chem. 2010;10(15):1527-43. Review.

PMID:
20583994
2.

Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2).

Horti AG, Gao Y, Ravert HT, Finley P, Valentine H, Wong DF, Endres CJ, Savonenko AV, Dannals RF.

Bioorg Med Chem. 2010 Jul 15;18(14):5202-7. doi: 10.1016/j.bmc.2010.05.058. Epub 2010 May 25.

3.

Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging.

Gao M, Wang M, Miller KD, Hutchins GD, Zheng QH.

Bioorg Med Chem. 2010 Mar 15;18(6):2099-106. doi: 10.1016/j.bmc.2010.02.011. Epub 2010 Feb 10.

PMID:
20189815
4.

Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor.

Fujinaga M, Kumata K, Yanamoto K, Kawamura K, Yamasaki T, Yui J, Hatori A, Ogawa M, Yoshida Y, Nengaki N, Maeda J, Zhang MR.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1565-8. doi: 10.1016/j.bmcl.2010.01.074. Epub 2010 Jan 21.

PMID:
20137936
5.

Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging.

Evens N, Muccioli GG, Houbrechts N, Lambert DM, Verbruggen AM, Van Laere K, Bormans GM.

Nucl Med Biol. 2009 May;36(4):455-65. doi: 10.1016/j.nucmedbio.2009.01.009. Epub 2009 Mar 26.

PMID:
19423014
6.

Emerging strategies for exploiting cannabinoid receptor agonists as medicines.

Pertwee RG.

Br J Pharmacol. 2009 Feb;156(3):397-411. doi: 10.1111/j.1476-5381.2008.00048.x. Review.

7.

Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain.

Horti AG, Van Laere K.

Curr Pharm Des. 2008;14(31):3363-83. Review.

PMID:
19075713
8.

Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.

Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, El Kouhen O, Hooker BA, Pai M, Wensink EJ, Salyers AK, Chandran P, Zhu CZ, Zhong C, Ryther K, Gallagher ME, Chin CL, Tovcimak AE, Hradil VP, Fox GB, Dart MJ, Honore P, Meyer MD.

J Pharmacol Exp Ther. 2009 Jan;328(1):141-51. doi: 10.1124/jpet.108.145011. Epub 2008 Oct 17.

9.

Labelling and biological evaluation of [(11)C]methoxy-Sch225336: a radioligand for the cannabinoid-type 2 receptor.

Evens N, Bosier B, Lavey BJ, Kozlowski JA, Vermaelen P, Baudemprez L, Busson R, Lambert DM, Van Laere K, Verbruggen AM, Bormans GM.

Nucl Med Biol. 2008 Oct;35(7):793-800. doi: 10.1016/j.nucmedbio.2008.07.004.

PMID:
18848664
10.

Cannabinoid CB2 receptors in human brain inflammation.

Benito C, Tolón RM, Pazos MR, Núñez E, Castillo AI, Romero J.

Br J Pharmacol. 2008 Jan;153(2):277-85. Epub 2007 Oct 15. Review.

11.

Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.

Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L, Mora Z, Tagliaferro P, Gardner E, Brusco A, Akinshola BE, Liu QR, Hope B, Iwasaki S, Arinami T, Teasenfitz L, Uhl GR.

Ann N Y Acad Sci. 2006 Aug;1074:514-36. Review.

PMID:
17105950
12.

Pharmacological actions of cannabinoids.

Pertwee RG.

Handb Exp Pharmacol. 2005;(168):1-51. Review.

PMID:
16596770
13.

Cannabinoid CB1 receptors control conditioned drug seeking.

De Vries TJ, Schoffelmeer AN.

Trends Pharmacol Sci. 2005 Aug;26(8):420-6. Review.

PMID:
15992935
14.

Cannabinoid receptors and their relationships with neuropsychiatric disorders.

Gambi F, De Berardis D, Sepede G, Quartesan R, Calcagni E, Salerno RM, Conti CM, Ferro FM.

Int J Immunopathol Pharmacol. 2005 Jan-Mar;18(1):15-9. Review.

PMID:
15698507
15.

Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature.

Akerman ME, Pilch J, Peters D, Ruoslahti E.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2040-5. Epub 2005 Feb 1.

16.

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG.

Pharmacol Rev. 2002 Jun;54(2):161-202. Review.

17.

Effects of cannabinoids on energy metabolism.

Guzmán M, Sánchez C.

Life Sci. 1999;65(6-7):657-64. Review.

PMID:
10462066
18.

Pharmacology of cannabinoid CB1 and CB2 receptors.

Pertwee RG.

Pharmacol Ther. 1997;74(2):129-80. Review.

PMID:
9336020
19.

Cellular effects of cannabinoids.

Martin BR.

Pharmacol Rev. 1986 Mar;38(1):45-74. Review.

PMID:
2872689

Supplemental Content

Support Center